Searle & CO. Has $3.69 Million Stake in Eli Lilly and Company (NYSE:LLY)

Searle & CO. boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 533.2% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,332 shares of the company’s stock after purchasing an additional 5,332 shares during the quarter. Eli Lilly and Company accounts for about 1.0% of Searle & CO.’s portfolio, making the stock its 25th largest holding. Searle & CO.’s holdings in Eli Lilly and Company were worth $3,691,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Simon Quick Advisors LLC raised its position in shares of Eli Lilly and Company by 10.5% in the 4th quarter. Simon Quick Advisors LLC now owns 2,927 shares of the company’s stock valued at $1,706,000 after buying an additional 278 shares in the last quarter. Clear Harbor Asset Management LLC acquired a new position in shares of Eli Lilly and Company in the 4th quarter valued at approximately $363,000. Terril Brothers Inc. raised its position in shares of Eli Lilly and Company by 113.2% in the 4th quarter. Terril Brothers Inc. now owns 808 shares of the company’s stock valued at $471,000 after buying an additional 429 shares in the last quarter. Hartline Investment Corp raised its position in shares of Eli Lilly and Company by 1.1% in the 4th quarter. Hartline Investment Corp now owns 21,934 shares of the company’s stock valued at $12,786,000 after buying an additional 248 shares in the last quarter. Finally, Meritage Portfolio Management raised its position in shares of Eli Lilly and Company by 23.4% in the 4th quarter. Meritage Portfolio Management now owns 6,377 shares of the company’s stock valued at $3,717,000 after buying an additional 1,208 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 0.6 %

Shares of LLY traded down $4.35 during trading hours on Wednesday, hitting $776.75. 2,762,349 shares of the stock were exchanged, compared to its average volume of 3,067,435. Eli Lilly and Company has a fifty-two week low of $399.26 and a fifty-two week high of $800.78. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. The business has a 50-day moving average of $761.41 and a 200-day moving average of $669.21. The firm has a market capitalization of $738.04 billion, a P/E ratio of 133.47, a price-to-earnings-growth ratio of 1.61 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, topping the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.62 earnings per share. On average, research analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the stock. JPMorgan Chase & Co. boosted their target price on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the company an “overweight” rating in a research report on Wednesday. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Citigroup lifted their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 target price on the stock. in a report on Wednesday, February 21st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $742.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.